![]() pain market, the acquisition of Qualitest is a forward-thinking play to keep Endo one step ahead of the game. With more than 90% of all pain prescriptions now filled by generic drugs in the $15 billion U.S. "The transaction provides Endo with an enhanced competitive position and critical mass in the generics market and when combined with our growing Branded Pharmaceuticals and Devices & Services businesses, makes us a more comprehensive healthcare solutions provider," said president and CEO of Endo, David Holveck. The new entity will also have a stronger pipeline of abbreviated new drug applications, with 46 under active FDA review in multiple therapeutic areas including pain, urology, CNS, as well as oncology and hypertension, and 24 under development. The deal, which significantly broadens Endo's range of generics with 175 added product families, will create a combined company with revenues of approximately $2.0 billion on a pro forma basis for fiscal 2010 and more than 3,000 employees. Thirty-two of Qualitest's products are listed among the top 250 generics by total prescription (TRx) volume. Huntsville, Alabama-based Qualitest manufactures controlled substances from its facilities in the U.S., which make up approximately 40% of its product portfolio, with liquids making up the remaining 17% of its portfolio. ![]() U.S.-based specialty healthcare company Endo Pharmaceuticals (Nasdaq: ENDP) has agreed to buy Qualitest Pharmaceuticals, the sixth largest generic pharmaceutical company in the U.S., for around $1.2 billion in cash from London-based buyout shop Apax Partners, it said Tuesday. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. Deborah has also completed stints at The Times, The Independent and The Economist. She has written about numerous issues surrounding the private equity market including fundraising in the current economic climate, turnaround and distressed debt investing, and the IPO market in general. Deborah graduated with a Masters in International Journalism from City University in 2008 before moving on to become deputy editor of private equity trade journal unquote" UK.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |